Preview Mode

Home
> Stocks
> AMGN stock

Stay informed on AMGN stock with the most important news summaries, insider trading, valuation highlights and analyst recommendations

AMGN stock news: A summarized overview for you, just the bottom line of the most recent news items!

Last Updated: October 09, 2024
  • Unlock Amgen's Intrinsic Value: A Valuation Guide
    • 💹 Dive into Amgen's investment potential! With shares estimated at $242, that's a juicy 26% upside from today's price – a golden opportunity for those eyeing value stocks with promising growth prospects.
    • 🔍 Amgen shines with strong fundamentals: steady revenue growth, solid cash flow, and a robust balance sheet. This financial fortitude allows for continued R&D investments and shareholder returns. Talk about a winning combo!
    • 🚀 Keep an eye on Amgen in the biotech world! Their innovative therapies, strategic acquisitions, and rich product pipeline offer a thrilling ride towards future healthcare trends. Perfect for investors aiming for long-term growth.
  • Amgen Partners with MediLink on New SCLC Therapy
    • Amgen and MediLink are joining forces to tackle small-cell lung cancer (SCLC) with a promising new therapy! Amgen's drug development prowess combined with MediLink's cutting-edge antibody platform could change the game for this aggressive cancer. 📈
    • Keep an eye on this partnership, folks! A successful rollout might just be the revenue booster and stock performance enhancer both Amgen and MediLink have been looking for. 💰
    • For investors, this is a big-ticket collaboration with potential market-moving implications. Savvy traders might find opportunities in tracking their progress and developments closely. 🤓
  • Add Amgen to Your October Dividend Stock Picks
    • Amgen stands out in a tough economy with strong performance and reliable dividend payouts, making it a must-watch for investors this October. 💼📈
    • Analysts praise Amgen's vibrant R&D efforts, propelling a pipeline of promising new drugs—an appealing aspect driving financial success and investor interest.
    • For traders eyeing dividend stocks, Amgen's blend of consistent payouts and growth potential is a smart pick to consider adding to your portfolio this month.

Real-time price chart of AMGN stock

Stay up-to-date with the latest performance of Amgen, (AMGN) through our real-time stock chart, providing live insights into its market movements

AMGN stock valuation - less noise, just the highlights

  • **Strong Forward P/E Ratio:** Amgen's (AMGN) forward P/E ratio of 15.29 suggests that the stock is priced attractively compared to its current P/E ratio of 54.73. This indicates that investors are anticipating significant growth in earnings, providing a more optimistic long-term valuation outlook. The forward P/E aligns with the idea that Amgen's future profitability might justify its current market cap.
  • **Efficient Profitability with a Balanced PEG Ratio:** Amgen's PEG ratio of 13.62, although higher than 1, indicates that the stock balances its price with anticipated earnings growth effectively. This PEG reflects Amgen's ability to grow its earnings in relation to its share price, making it an appealing pick for investors looking at AMGN valuation metrics that factor both growth and price.
  • **Sustainable Growth with Sound EPS Projections:** The EPS growth forecast for the next year at 6.41% and next five years at 4.02% highlights AMGN's potential for steady earnings growth. These figures, combined with the positive sales growth of 3.42% over the past five years, offer a clear snapshot that Amgen is positioned for sustainable financial performance, which is crucial for both AMGN valuation and Amgen valuation.

Stay informed with the latest AMGN stock analyst recommendations:

  • Investors should note the diversity of opinions among top-tier firms, which underscores the need to consider a broad spectrum of analysis when evaluating AMGN. Key firms like Barclays and William Blair have moved their ratings from 'Underweight' or 'Market Perform' to recommend 'Equal Weight' or 'Outperform', suggesting evolving perspectives on the stock’s valuation and potential growth.
  • Despite some downgrades, such as from Wells Fargo and Leerink Partners, there is a trend of increasing price targets among analysts who have adjusted their outlooks. For instance, even after the downgrade, Wells Fargo raised their price target from $320 to $335, reflecting underlying confidence in Amgen's value proposition.
  • The recent analyst activity surrounding AMGN stock highlights significant upgrades and initiates that indicate a growing confidence in Amgen’s future potential. Notably, Cantor Fitzgerald initiated coverage with an 'Overweight' rating and a high price target of $405, suggesting strong buy sentiment. BMO Capital Markets and RBC Capital Mkts have also upgraded AMGN to 'Outperform', pointing toward positive expectations and stock performance.

Stay updated on AMGN stock insider trading with these key points:

  • These AMGN insider trades provide a distinct insight for investors looking for long-term engagement with the stock or those aiming for short-term gains. The consistency in sell-off by insiders at a slightly higher stock valuation as seen in the recent $313 sales suggests a strategic alignment possibly to lock gains. Therefore, a consistent insider selling trend at specific share prices may encourage investors to reassess their positions, potentially leading to a "sell" or "hold" decision depending on individual risk tolerance and market outlook.
  • Recent notable insider trading activity for AMGN stock includes significant sales by key executives like the SVP & CCO, and the EVP, General Counsel & Secretary. Such trades, especially from high-ranking roles involved in compliance, legal, or financial oversight, can be crucial signals. Investors may view these sales with caution, as they could indicate insiders' anticipation of a potential downturn or profit-taking at current valuations.
  • The pattern of recent AMGN insider trades shows a recurring theme of sales at sizable volumes. For instance, the sale by Jonathan P. Graham, the EVP & General Counsel, involved 10,000 shares for over $2.7 million. Large volume sales at once by insiders can often signal their lack of confidence in the short to medium-term stock performance. Traders might see this as a "sell" signal, reflecting possible strategic moves that insiders might expect.

AMGN technical analysis

Unlock insights to make smarter investment decisions with this real-time technical analysis tool. Dive in to see the latest buy and sell signals tailored for today's dynamic market. Get the market's inside scoop in a flash! Peek at our fun and user-friendly ratings to see what it is whispering about your AMGN stock, within various timeframes.

Join the Discussion: What's your outlook on AMGN stock's performance?

Are you considering investing in AMGN or have you already done so? Share your thoughts below with the investor and trader community at ForexLive.com, share your angles, analysis, predictions, or questions about AMGN in the comments below! Your input matters to us.

Please note that this content regarding AMGN stock is for informational purposes only, includes opinions and not recommendations, and is not intended as investment or trading advice; invest in and/or trade AMGN at your own risk only.

Explore additional stocks:

Discover Ameriprise Financial stock with its new summaries, insider trading, valuation highlights and analyst recommendations

GMT 00:00:00
LON 00:00:00
NY 00:00:00
TKYO 00:00:00
SYD 00:00:00

Stock Daily Updates

Must Read

Follow Us

Read our Terms, Cookies and Privacy Notice

Manage cookies

High risk warning: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all your initial investment; do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading and seek advice from an independent financial or tax advisor if you have any questions.

Advisory warning: FOREXLIVE™ is not an investment advisor, FOREXLIVE™ provides references and links to selected news, blogs and other sources of economic and market information for informational purposes and as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and FOREXLIVE™ specifically hereby acknowledges clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Forex dealer. Any news, opinions, research, data, or other information contained within this website is provided on an "as-is" basis as a general market commentary and does not constitute investment or trading advice, and we do not purport to present the entire relevant or available public information with respect to a specific market or security. FOREXLIVE™ expressly disclaims any liability for any lost principal or profits which may arise directly or indirectly from the use of or reliance on such information, or with respect to any of the content presented within its website, nor its editorial choices.

Disclaimer: FOREXLIVE™ may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Finance Magnates CY Limited

!"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}